Volume Spike Investor

AEterna Zentaris Inc. (NASDAQ: AEZS) is surging on word that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), its partner and licensee for perifosine in the North American market, received an FDA orphan-drug designation for this compound for the treatment of multiple myeloma.  Keryx had already announced last month that it reached agreement with the FDA over a Special Protocol Assessment on the Phase III trial design.  At 8:40 AM EST: Keryx is up 26% at $1.97, what is above its 52-week high of $1.88 and we have seen 440,000 shares trade hands versus average daily volume of 1.55 million shares.  AEterna Zentaris is up 12% at $1.18 on right at 100,000 shares versus an average volume of close to 800,000 shares.  AEZS has a 52-week high of $3.25 so that is not as big of a break-out for it. -JON OGG